Abstract: The present invention relates to Carnitine-Palmitoyl-Transferase-1 (CPT-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject. The invention also relates to pharmaceutical compositions comprising a Carnitine-Palmi-toyl-Transferase-1 (CPT-1) inhibitor for said use.

Abstract: Provided herein are methods of potentiating an effect of an anti-cancer drug in a subject diagnosed with cancer, the method including administering to the subject a combination therapy including: an effective amount of 7-ethynyl-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (BZD-1); and an anti-cancer drug.

Abstract: Described herein are methods of treating acute heart failure in a subject in need thereof, comprising administering a therapeutically effective amount of istaroxime by intravenous infusion over a period of at least 24 hours wherein the therapeutically effective amount of istaroxime is between about 0.1 ?g/kg/min and about 3.0 g/kg/min; and wherein the subject's acute heart failure is treated.

Abstract: The present invention is a pharmaceutical kit for combined parenteral administration, comprising a first formulation containing a first drug, and a second formulation containing a second drug and a parenteral drug delivery system, and it can be used for preventing, reducing or treating an inflammatory reaction of a subject caused by the parenteral drug delivery system of the second formulation, controlling decomposition of the parenteral drug delivery system contained in the second formulation, or increasing bioavailability of the second drug contained in the second formulation.

Abstract: The invention relates to a rocuronium composition providing no or less vascular pain to patients upon injection. The rocuronium composition has a pH of 2.5 to 3.5 and a titratable acidity of not more than 35 mEq. The rocuronium composition is stable upon thermal sterilization. Further, the rocuronium composition is stable upon storage at room-temperature.

Abstract: The present disclosure relates to microbial-triggered small and large intestinal drug delivery (SLIDD) oral formulation and method of preparation thereof. The formulation delivers the active ingredient or the drug to the predetermined location in the GI tract with success.

Abstract: The present disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of withaferin A and an immune checkpoint blocker. Further, the cancer to be treated may be resistant, have developed resistance, or may be susceptible to resistance to treatment with the immune checkpoint blocker alone or in combination with another therapeutic agent other than withaferin A.

Abstract: Methods and compositions for treating and/or preventing Alzheimer's disease (AD), and/or for reducing one or more amyloid beta peptides and/or phosphorylated tau (p-tau) in the brain of a subject. The methods can include administering a composition comprising melatonin and cannabidiol (CBD).

Abstract: A composition including a cannabinoid and an anti-cancer agent and methods of treating lung cancer using said composition.

Abstract: Compositions and methods of use of treatment of one or more of ovarian cancer, endometrial cancer, head and neck cancer, noncancerous gynecological disorders, and estrogen sensitive cancers, the composition comprising an effective amount of a cannabinoid and a flavonoid wherein the method comprises administering to a patient in need thereof an effective amount of the composition and optionally administering the composition concomitantly with a chemotherapeutic agent.

Abstract: Novel antimicrobial compositions may comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyrimidine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria.

Abstract: Methods and pharmaceutical compositions are described for treating a variety of chronic human afflictions including anxiety disorders, eating disorders, chronic pain, depression, addictive disorders, dementia (e.g., Alzheimer's disease, frontotemporal dementia, Lewy body disorder, and vascular dementia), traumatic brain injury (TBI) and mild cognitive impairment. A sub-hallucinogenic dose of a psychedelic tryptamine, including for example psilacetin and psilocybin, along with a low dose of D-cycloserine are administered to human subjects in order to modify neural pathways to treat the chronic affliction.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: Methods of feeding animals are disclosed wherein providing feed additives are provided that modulate the gut microbiome to improve the health, nutrition, and growth performance. Methods of modulating the microbial species present in the gastrointestinal tract of an animal are also disclosed. Such modulation includes, for example, modulating the level or function of microbial species.

Abstract: The present invention discloses a pharmaceutical composition comprising azvudine and a chemotherapeutic agent. The pharmaceutical composition of the present invention shows a good synergistic effect in antitumor, and can reduce the dosage of chemotherapeutic agent, and improve the therapeutic effect and safety, thereby achieving the goal of prolonging the survival of patients.

Abstract: The invention relates to 5-fluoro-2?-deoxyuridine-5?-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, in particular by intravenous infusion for a continuous period of up to 10 hours. The invention also relates to methods of treating cancer by administration of NUC-3373 to particular sub-groups of cancer patient. The invention further relates to methods for selecting a patient for treatment with NUC-3373.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dentin-dental pulp disease or periodontal disease, a quasi-drug composition for preventing or improving dentin-dental pulp disease or periodontal disease or a health functional food composition for preventing or improving dentin-dental pulp disease or periodontal disease, all of which comprise a LPAR2 (lysophosphatidic acid receptor 2) inhibitor.

Abstract: Inhibitor compounds of type 2 iodothyronine deiodinase (D2) are described for use in the therapeutic treatment of muscle wasting and/or in a muscle and/or skin regenerative therapeutic method. A pharmaceutical composition comprising a type 2 iodothyronine deiodinase (D2) inhibitor compound in a pharmaceutically acceptable vehicle, as well as in combination with optional excipients, diluents and adjuvants, is also described.

Abstract: The object of the invention relates to an association of molecular oxygen and hyaluronic acid or its salts for use in the treatment of symptomatology associated with vulvar vestibulitis.

Abstract: Described herein are compositions and methods for increasing a glucose uptake of differentiated adipocytes using heparan sulfate mimetics comprising a polymer backbone comprising sulfated di saccharides, the polymer backbone linked to a cell membrane anchoring portion, wherein the heparan sulfate mimetic associates with the cell membrane or binds to membrane surface proteins of the pre-adipocytes and the adipocytes.

Abstract: The present invention provides a pharmaceutical composition comprising: a biodegradable multi-branched copolymer comprising at least three polyester arms attached to a central core which comprises a polyether, and wherein the multi-branched copolymer is substantially insoluble in aqueous solution, further comprising at least one pharmaceutically active ingredient.

Abstract: The present invention provides systems for transporting and/or delivering nitric oxide into and/or through an epithelial layer, such as skin and/or mucosa, comprising an alpha-hydroxy acid (AHA) and a nitric oxide source from which nitric oxide (NO) is generated or released.

Abstract: A method and composition to extract of several processed herbal medicinal plants and an herbal tea composition for ingestion which contains the extract. The functional herbal extraction method and composition is used to relieve the symptoms of cough and throat discomfort. This composition creates a synergy between different ingredients that works to suppress cough, yellow or green phlegm, sore throat and specifically to treat hot cough. The composition can include Shi Gao, Hai Fu Shi, Chuan Bei Mu, Tian Zhu Huang, Ban Xia, Yu Xing Cao, Tian Kui Zi, Gan Cao, Tian Nan Xing, Chai Hu, Huang Qin, Zhi Shi, Bai Shao, Chen Pi, Kuan Dong Hua, Zi Wan, Sheng Jiang. The effectiveness of the herbal tea is at least partially dependent on the desired means of preparation and administering the composition.

Abstract: The present invention pertains to the use of the calcium-sensing receptor (CaSR)-activating nutrients (designated as “CaSR-based nutrients”) for the prevention and/or treatment of diarrheal diseases and inflammation in the gastrointestinal tract. In one embodiment, the current invention is formulated for oral administration. The anti-diarrheal composition of the present invention is useful for treating diarrheal and gastrointestinal inflammatory conditions in infants and young children.

Abstract: The composition for treating bone loss is a solution of silver nanoparticles in an ethanolic extract of Leptadenia plant leaves. The composition is prepared by extracting dried Leptadenia plant leaf powder in ethanol for 24 hours at room temperature with constant stirring. A sample of the extract is fractionated by column chromatography, and the fractions are tested to determine the most effective fraction for stimulating osteoblast formation from bone marrow-derived mesenchymal stem cells (BMSCs). This fraction is used to synthesize green silver nanoparticles by adding the extract fraction to a solution of silver nitrate with constant stirring for 24 hours at room temperature. A portion of the Leptadenia extract is added to the resulting silver nanoparticles to stimulate osteoblast formation in cultures of BMSCs. The composition may be used to form drug compositions for treating bone loss.

Abstract: The composition for treating bone loss is a solution of silver nanoparticles in an ethanolic extract of Leptadenia plant leaves. The composition is prepared by extracting dried Leptadenia plant leaf powder in ethanol for 24 hours at room temperature with constant stirring. A sample of the extract is fractionated by column chromatography, and the fractions are tested to determine the most effective fraction for stimulating osteoblast formation from bone marrow-derived mesenchymal stem cells (BMSCs). This fraction is used to synthesize green silver nanoparticles by adding the extract fraction to a solution of silver nitrate with constant stirring for 24 hours at room temperature. A portion of the Leptadenia extract is added to the resulting silver nanoparticles to stimulate osteoblast formation in cultures of BMSCs. The composition may be used to form drug compositions for treating bone loss.

Abstract: The composition for treating bone loss is a solution of silver nanoparticles in an ethanolic extract of Leptadenia plant leaves. The composition is prepared by extracting dried Leptadenia plant leaf powder in ethanol for 24 hours at room temperature with constant stirring. A sample of the extract is fractionated by column chromatography, and the fractions are tested to determine the most effective fraction for stimulating osteoblast formation from bone marrow-derived mesenchymal stem cells (BMSCs). This fraction is used to synthesize green silver nanoparticles by adding the extract fraction to a solution of silver nitrate with constant stirring for 24 hours at room temperature. A portion of the Leptadenia extract is added to the resulting silver nanoparticles to stimulate osteoblast formation in cultures of BMSCs. The composition may be used to form drug compositions for treating bone loss.

Abstract: An angiogenesis material, a bone-regeneration-promoting material, a method for producing an angiogenesis material and a method for producing a bone-regeneration-promoting material which particularly improve angiogenesis capacity, angiogenesis capacity and osteogenesis capacity, are particularly effective for bone regeneration and are expected to be applied not only to bone regeneration but also to regeneration of various tissues in which angiogenesis is required are provided. These are an angiogenesis material containing a composite of a metal-octacalcium phosphate-containing material containing octacalcium phosphate and a metal element and a bioabsorbable polymer, a bone-regeneration-promoting material using the same, and production methods thereof.

Abstract: The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.

Abstract: The invention provides antigen binding domains that bind myeloid cell surface antigen CD33 protein comprising the antigen binding domains that bind CD33, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Abstract: The present disclosure provides a TCR-T cell for tumor-killing, wherein the TCR-T cell is a T cell carrying a TCR that recognizes a tumor antigen, and the TCR in the TCR-T cell is derived from any one or more of the following T cells: 1) a CD4 T cell expressing one or more of TNFRSF18, CXCL13, TNFRSF4, TNFSF8, ENTPD1, ACP5, LAYN, TNFRSF9, CTLA4, CD200 and TIGIT genes in the tumor; and 2) a CD8 T cell expressing one or more of TNFRSF18, CXCL13, CXCR6, GALNT2, ENTPD1, ACP5, HAVCR2, LAYN, TNFRSF9, CTLA4 and CD109 genes in the tumor. The TCR-T cell according to the present disclosure can be effectively applied to the treatment of a tumor, especially in an immunotherapy.

Abstract: The present invention relates to the field of therapeutic treatment, particularly of cell therapy based on CD16+ cells and NK (Natural Killer) cells. In particular, the invention relates to a pharmaceutical composition comprising a CD16+ cell, a NK cell or a NK cell precursor, in combination with a recombinant polypeptide comprising a modified Fc region, in particular a modified CH2 domain.

Abstract: A combination cancer therapy comprising a small molecule drug conjugate (SMDC), which targets a cell-surface receptor on an immunosuppressive cell or a cancerous cell, and cytotoxic lymphocytes, which express a chimeric antigen receptor (CAR); and a method of treating a patient for cancer using the same.

Abstract: The present invention generally relates to Claudin18.2 chimeric antigen receptors. T cells engineered to express Claudin18.2 chimeric antigen receptors (CARs), and uses for treating diseases associated with expression of Claudin18.2.

Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

Abstract: This disclosure provides for peptides useful for vaccination and other applications, engineered T cell Receptors (TCRs), cells comprising the peptides and TCRs, and methods of making and using the peptides and TCRs. The current disclosure relates to TCRs that specifically recognize SARS-Cov-2 HLA-A2 restricted peptide from membrane glycol-protein (MGP), MGP-65: FVLAAVYRI (SEQ ID NO:22).

Abstract: Disclosed are antigen binding molecules that bind to Dickkopf-1 (DKK1) P20 peptide in the context of MHC-HLA-A2 (i.e., a DKK1-A2 complex). Such antigen binding molecules can by antibodies, antibody fragments, bi-specific antibodies, immunotoxins or the chimeric antigen receptor portion of a chimeric antigen receptor T cell. Also disclosed herein are methods of using said antigen binding molecules for the treatment of cancer.

Abstract: The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides chimeric antigen receptor (CAR) T cells that are modified to maintain functionality under conditions in which unmodified CAR T cells display exhaustion. Compositions and methods disclosed herein find use in inhibiting or reversing CAR T cell exhaustion (e.g., by modulating CAR surface expression) thereby enhancing CAR T cell function. Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

Abstract: Provided herein, in various embodiments, are mammalian cells (e.g., immune effector cells) comprising a nucleotide sequence encoding an exogenous fusogen. Also provided herein, in various embodiments, are methods of treating cancer in a subject in need thereof, comprising administering to the subject mammalian cells (e.g., immune effector cells) disclosed herein. Also provided herein, in various embodiments, are methods of killing a cancer cell, comprising contacting the cancer cell with mammalian cells (e.g., immune effector cells) disclosed herein.

Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

Abstract: Compounds, compositions, combined preparations, and multiple-dose formulations, for use in the treatment of tissue damage or injury, in particular, for example, spinal cord injury and tendon injury, are described. Methods of treatment of tissue damage or injury using the compounds, compositions, combined preparations, or multiple-dose formulations, are also described. Vitamin A. and optionally one or more regenerative cells, is used to inhibit scar tissue formation in a subject, which is a necessary prerequisite for successful tissue regeneration following tissue damage or injury. Vitamin A and compositions comprising vitamin A, for use in the treatment of pulmonary fibrosis, including pulmonary fibrosis caused by respiratory infection, are also described. Methods of treatment of pulmonary fibrosis using vitamin A and compositions are also described. Vitamin A.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Abstract: Compositions and methods for delivering a protein of interest such as a cell homing molecule (e.g., CXCR4) into host cells (e.g., to hematopoietic cells). The compositions and methods provided herein may be used to enhance homing and long-term engraftment of hematopoietic cells post transplantation.

Abstract: The present invention relates to pluripotent stems cells restricted in their capability to differentiate into cell lineages different from Dopaminergic neuron progenitor cells and derivatives thereof by specific gene knockouts. In particular, the present invention relates to dopaminergic neuron progenitor cells or cell derivatives thereof obtained from these lineage-restricted pluripotent stem cells and uses thereof.

Abstract: Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express one or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent.

Abstract: Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express one or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent.

Abstract: The invention relates to mesenchymal stem cell derived exosomes produced by a method comprising the steps of, performing a method of producing a clonal mesenchymal stem cell line capable of producing exosomes (MSC-derived extracellular vesicles) comprising the steps of, providing human induced pluripotent stem cells (hiPSCs), generating therefrom an immortalized clonal cell line of mesenchymal stem cells (IMSCs), characterizing the potential of the IMSCs to produce exosomes, cultivating the desired IMSCs such that the IMSCs produce exosomes, isolating the exosomes.

Abstract: Disclosed herein are methods and compositions comprising placental adherent stromal cells for treating peripheral ischemic disease, for example critical limb ischemia in specific patient subpopulations; and methods of selecting subjects having peripheral ischemic disease, for example critical limb ischemia, amenable for treatment with placental adherent stromal cells.

Abstract: The invention relates to processing methods to produce Bee Product Extracts produced from a Bee Product such as honey, pollen, waxes, or royal jelly; and in particular a Bee Product Extract produced from manuka honey; their uses, methods of preparation and methods of their detection and analysis. The Bee Product Extract of the invention contains phenolics, minerals and proteins coordinated in a complex that undergoes photo-Fenton chemistry process to generate high energy short lived radicals, including Hydroxyl radicals and superoxide radicals. The formulated Bee Product Extract can provide a topical form to be used as a spray, mist or serum for the treatment of a wide range of human and animal diseases and to maintain health and well-being.

Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.